Quantgene is a biotechnology company at the forefront of AI-powered genomics, dedicated to revolutionizing early cancer detection and extending healthy human lifespans. Their core mission revolves around harnessing deep genomic intelligence to empower proactive health management. Quantgene's flagship product, the Serenity™ liquid biopsy test, aims to detect multiple cancer types from a single blood draw at their earliest, most treatable stages, significantly improving patient outcomes. They combine advanced next-generation sequencing (NGS) with sophisticated artificial intelligence algorithms to analyze complex genomic data, offering personalized insights for disease prevention and longevity.
The headquarters serves as the central hub for Quantgene's research and development, corporate strategy, clinical operations, data science, and administrative functions.
Likely features state-of-the-art laboratory facilities for genomic sequencing and analysis, collaborative workspaces designed to foster innovation, and advanced computational infrastructure for AI development.
Quantgene's work culture is characterized by a strong emphasis on scientific excellence, innovation, and a mission-driven approach to tackling complex health challenges. It fosters collaboration among a diverse team of scientists, engineers, clinicians, and business professionals dedicated to advancing personalized medicine.
Its location in Southern California provides access to a rich ecosystem of top-tier research institutions, a skilled talent pool in biotech and AI, and a vibrant venture capital community, crucial for growth and collaboration.
While headquartered in Santa Monica, California, with a presence in Berlin, Germany, Quantgene's reach is global. They collaborate with international research institutions, healthcare providers, and partners to advance their genomic technologies and make their innovative diagnostic tests accessible to a wider population. Their AI and data analysis capabilities support clinical studies and deployments across different regions, aiming to impact cancer care and longevity on a global scale.
2400 Ocean Park Blvd, Suite 300
Santa Monica
California
USA
Address: Undisclosed specific street address, likely a research or business development office.
Facilitating partnerships with European research institutions and healthcare providers, navigating EU regulatory landscapes, and expanding Quantgene's presence in the European biotech sector.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Quantgene' leadership includes:
Quantgene has been backed by several prominent investors over the years, including:
Public information regarding specific executive new hires or exits at Quantgene in the immediate last 12 months is limited. Companies of this stage often announce significant C-suite changes through targeted press releases or industry publications. Any recent changes would typically focus on strengthening leadership in clinical development, commercialization, or AI research.
Discover the tools Quantgene uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Quantgene likely utilizes common professional email formats. The most probable formats are [first_initial][last]@quantgene.com or [first].[last]@quantgene.com. Given the company's modern approach, the [first_initial][last] format might be slightly more common for brevity.
[first_initial][last]@quantgene.com (e.g., jbhakdi@quantgene.com) or [first].[last]@quantgene.com (e.g., johannes.bhakdi@quantgene.com)
Format
jbhakdi@quantgene.com
Example
80%
Success rate
GlobeNewswire • April 10, 2024
Quantgene presented data at the American Association for Cancer Research (AACR) Annual Meeting 2024, highlighting the performance of its AI-driven genomic platform. The presentation focused on the SERENITY™ test's ability for early cancer detection and its broader applications in longevity and preventative medicine....more
Endpoints News • February 15, 2023
Quantgene and Personalis, Inc. announced a collaboration to combine their technologies to enhance personalized cancer treatment and monitoring. This partnership aims to leverage Quantgene's AI with Personalis's advanced genomics capabilities....more
PR Newswire • October 12, 2022
Quantgene announced the appointment of L. Michael Snyder, M.D., as its Chief Medical Officer. Dr. Snyder brings extensive experience in laboratory medicine and diagnostics to guide Quantgene's clinical strategy and product development....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Quantgene, are just a search away.